Brown ZJ - Search Results

1

Mutational Landscape and Precision Medicine in Hepatocellular Carcinoma.

Gorji L, Brown ZJ, Pawlik TM. Gorji L, et al. Among authors: brown zj. Cancers (Basel). 2023 Aug 23;15(17):4221. doi: 10.3390/cancers15174221. Cancers (Basel). 2023. PMID: 37686496 Free PMC article. Review.

2

Impact of care fragmentation on the outcomes of patients receiving neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma.

Brown ZJ, Labiner HE, Shen C, Ejaz A, Pawlik TM, Cloyd JM. Brown ZJ, et al. J Surg Oncol. 2022 Feb;125(2):185-193. doi: 10.1002/jso.26706. Epub 2021 Oct 2. J Surg Oncol. 2022. PMID: 34599756 Free PMC article.

3

Surgical management of intrahepatic cholangiocarcinoma.

Hewitt DB, Brown ZJ, Pawlik TM. Hewitt DB, et al. Among authors: brown zj. Expert Rev Anticancer Ther. 2022 Jan;22(1):27-38. doi: 10.1080/14737140.2022.1999809. Epub 2021 Nov 15. Expert Rev Anticancer Ther. 2022. PMID: 34730474 Review.

4

Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress.

Brown ZJ, Hewitt DB, Pawlik TM. Brown ZJ, et al. Expert Opin Investig Drugs. 2022 Apr;31(4):379-391. doi: 10.1080/13543784.2022.2008355. Epub 2021 Nov 25. Expert Opin Investig Drugs. 2022. PMID: 34788184 Review.

5

Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs.

Spolverato G, Glavas D, Hewitt DB, Brown ZJ, Capelli G, Bergamo F, Rizzato MD, Pawlik TM. Spolverato G, et al. Among authors: brown zj. Expert Opin Pharmacother. 2022 Mar;23(4):473-481. doi: 10.1080/14656566.2021.2020250. Epub 2021 Dec 29. Expert Opin Pharmacother. 2022. PMID: 34964678 Review.

6

A Scoping Review of the Classification, Diagnosis, and Management of Hepatic Adenomas.

Aziz H, Brown ZJ, Eskander MF, Aquina CT, Baghdadi A, Kamel IR, Pawlik TM. Aziz H, et al. Among authors: brown zj. J Gastrointest Surg. 2022 Apr;26(4):965-978. doi: 10.1007/s11605-022-05246-8. Epub 2022 Jan 26. J Gastrointest Surg. 2022. PMID: 35083725 Review.

7

Patient stratification in hepatocellular carcinoma: impact on choice of therapy.

Papaconstantinou D, Hewitt DB, Brown ZJ, Schizas D, Tsilimigras DI, Pawlik TM. Papaconstantinou D, et al. Among authors: brown zj. Expert Rev Anticancer Ther. 2022 Mar;22(3):297-306. doi: 10.1080/14737140.2022.2041415. Epub 2022 Feb 21. Expert Rev Anticancer Ther. 2022. PMID: 35157530 Review.

8

Biomarkers of intrahepatic cholangiocarcinoma: diagnosis and response to therapy.

Brown ZJ, Hewitt DB, Pawlik TM. Brown ZJ, et al. Front Biosci (Landmark Ed). 2022 Mar 5;27(3):85. doi: 10.31083/j.fbl2703085. Front Biosci (Landmark Ed). 2022. PMID: 35345317 Free article. Review.

9

Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.

Brown ZJ, Gregory S, Hewitt DB, Iacono S, Choe J, Labiner HE, Pawlik TM. Brown ZJ, et al. Surg Oncol. 2022 Jun;42:101748. doi: 10.1016/j.suronc.2022.101748. Epub 2022 Apr 1. Surg Oncol. 2022. PMID: 35395582 Review.

10

Current Perspectives on the Surgical Management of Perihilar Cholangiocarcinoma.

Hewitt DB, Brown ZJ, Pawlik TM. Hewitt DB, et al. Among authors: brown zj. Cancers (Basel). 2022 Apr 28;14(9):2208. doi: 10.3390/cancers14092208. Cancers (Basel). 2022. PMID: 35565335 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

84 results

Search Page